A Phase 1 interventional study of PF-06305591 and Placebo in Healthy, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-05-23.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
The study is designed to test safety tolerability and PK of single oral ascending doses of PF-06305591,
Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single ascending oral doses in fasted conditions
Drug: PF-06305591 · Drug: Placebo
Single ascending oral doses in fasted conditions
Drug: PF-06305591 · Drug: Placebo
Single ascending oral doses in fed conditions
Drug: PF-06305591 · Drug: Placebo
single dose, solution
matching placebo
single dose, solution
matching placebo
single dose, solution
matching placebo
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: 72 hr
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - 8)]
Time frame: 72 hr
This study is completed, as verified in May 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer